论文部分内容阅读
目的:观察黄芩苷联合拉米夫定治疗慢性乙型肝炎的疗效及对细胞免疫的影响。方法:120例慢性乙肝患者分为治疗组和对照组,对照组给予拉米夫定治疗,治疗组在给予拉米夫定的同时服用黄芩苷胶囊治疗。结果:治疗组治疗后ALT、AST、TBil分别降低至49.5±4.5U/L、54.4±6.9U/L、21.4±3.8μmol/L均低于治疗前及对照组(P<0.01);与对照组相比,治疗组患者HBe Ag转阴率、HBe Ag/HBe Ab血清转换率及HBV-DNA阴转率显著高于对照组;两组治疗后CD4+细胞亚群、CD4+/CD8+比例及NK细胞水平较治疗前增高、CD8+降低,且治疗组更为明显。结论:黄芩苷联合拉米夫定可以治疗慢性乙型肝炎,还可以抑制HBV DNA复制,并且增强细胞免疫功能。
Objective: To observe the curative effect of baicalin combined with lamivudine on chronic hepatitis B and its effect on cellular immunity. Methods: 120 patients with chronic hepatitis B were divided into treatment group and control group. The control group was treated with lamivudine. The treatment group was treated with baicalin capsule while lamivudine was given. Results: After treatment, ALT, AST and TBil decreased to 49.5 ± 4.5U / L, 54.4 ± 6.9U / L and 21.4 ± 3.8μmol / L, respectively, compared with those before treatment and in control group (P <0.01) HBeAg negative rate, HBeAg / HBe Ab seroconversion rate and HBV-DNA negative rate in treatment group were significantly higher than those in control group. After treatment, CD4 + cell subsets, CD4 + / CD8 + ratio and NK cells The levels were higher than before treatment, CD8 + decreased, and the treatment group was more obvious. Conclusion: Baicalin combined with lamivudine can treat chronic hepatitis B, but also inhibits HBV DNA replication and enhances cellular immune function.